The NanoBiotechnology Group is mainly focused on the use of bioactive molecules and nanoparticles in nanomedicine & nanotechnology. It possesses a multidisciplinary philosophy, combining the expertise of Dr. Alvaro Somoza, an expert in the use of modified oligonucleotides and nanostructures in nanomedicine, and Dr. Begoña Sot, an expert in protein engineering and therapeutic proteins. The group deals with several research lines, centered on the use of modified oligonucleotides and proteins to create new nanomedical tools and sensors.
– Nanoparticles in Drug Delivery, using different nanostructures to deliver different drugs and nucleic acids for the treatment of different diseases.
– The design of new strategies for efficient editing of Uveal Melanoma and Pancreatic cancer cell lines based on the delivery ofthe CRISPR system.
– Nanosensors for multiples diseases, such as Uveal, Melanoma, Pancreatic cancer or Duchenne Muscular Dystrophy.
– Modified magnetic nanoparticles for the treatment of pancreatic cancer. (NoCanTher project)
Dr. Begoña Sot´s group:
– The design of new strategies for efficient editing of Uveal Melanoma and Pancreatic cancer cell lines based on CRISPR proteins delivery.
– Design of new immunotherapy tools based in engineered molecular chaperones and gold nanoparticles able to load Antigen Presenting Cells with antigens and siRNAs for their use in immunotherapy.
– Effect of molecular chaperones in amyloid fibers assembly.
– Antibacterial activity of metal nanoparticles conjugated with modified bactericidal peptides.
Funding agency: Asociación Española Contra el CáncerNanomedicine Upscaling for Early
Funding agency: European Commission , H2020, REF: GA 685795
Funding agency: EuronanoMed II (MINECO). REF: PCIN-2016-167
Funding agency: MINECO, REF: SAF2014-56763-R
Seventh Framework Programme grant agreement no. 262943